Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021

doi:10.19401/j.cnki.1007-3639.2022.09.003

Abstract

Abstract:

Pancreatic neuroendocrine neoplasm (PanNEN) has a low incidence and strong heterogeneity. Research on molecular mechanism of PanNEN is gradually increasing. At the same time, the updates on clinical diagnosis, treatment and prognosis prediction of PanNEN patients are increasing. In addition to surgery and systemic treatment such as somatostatin analogs and tyrosine kinase inhibitors, there are unsolved problems and questions in the management of PanNEN patients, which emphasizes individualized treatment and multidisciplinary treatment. This article summarized the basic and clinical research progress of PanNEN in 2021.

Key words: Pancreatic neuroendocrine tumor, Molecular marker, Diagnosis, Prognosis, Treatment

CLC Number:

R735.9

GAO Heli, XU Jin, YU Xianjun. Updates on the research and management of pancreatic neuroendocrine neoplasm in 2021[J]. China Oncology, 2022, 32(9): 772-778.

References 54

[1]	ALI H, PAMARTHY R, VALLABHANENI M, et al. Pancreatic cancer incidence trends in the United States from 2000-2017: analysis of Surveillance, Epidemiology and End Results (SEER) database[J]. F1000Res, 2021, 10: 529. doi: 10.12688/f1000research.54390.1 pmid: 34527218
[2]	中国临床肿瘤学会指南工作委员会. 神经内分泌肿瘤诊疗指南(2021)[M]. 北京: 人民卫生出版社, 2021.
	Guideline Working Committee of Chinese Society of Clinical Oncology. Guidelines for the diagnosis and treatment of neuroendocrine tumors (2021)[M]. Beijing: People’s Medical Publishing House, 2021.
[3]	MANDAIR D, KHAN M S, LOPES A, et al. Prognostic threshold for circulating tumor cells in patients with pancreatic and midgut neuroendocrine tumors[J]. J Clin Endocrinol Metab, 2020, 106(3): 872-882. doi: 10.1210/clinem/dgaa822
[4]	OVERSOE S K, SORENSEN B S, TABAKSBLAT E M, et al. Cell-free DNA and clinical characteristics in patients with small intestinal or pancreatic neuroendocrine tumors[J]. Neuroendocrinology, 2022, 112(1): 43-50. doi: 10.1159/000514457
[5]	MALCZEWSKA A, WITKOWSKA M, WÓJCIK-GIERTUGA M, et al. Prospective evaluation of the NETest as a liquid biopsy for gastroenteropancreatic and bronchopulmonary neuroendocrine tumors: an ENETS center of excellence experience[J]. Neuroendocrinology, 2021, 111(4): 304-319. doi: 10.1159/000508106
[6]	MODLIN I M, KIDD M, FRILLING A, et al. Molecular genomic assessment using a blood-based mRNA signature (NETest) is cost-effective and predicts neuroendocrine tumor recurrence with 94% accuracy[J]. Ann Surg, 2021, 274(3): 481-490. doi: 10.1097/SLA.0000000000005026
[7]	VAN TREIJEN M J C, VAN DER ZEE D, HEERES B C, et al. Blood molecular genomic analysis predicts the disease course of gastroenteropancreatic neuroendocrine tumor patients: a validation study of the predictive value of the NETest®[J]. Neuroendocrinology, 2021, 111(6): 586-598. doi: 10.1159/000509091
[8]	LLOYD R V, OSAMURA R Y, KLOPPEL G, et al. WHO classification of tumours of endocrine organs[M]. 5th ed. Lyon: IARC WHO Classification of Tumours, 2019, 10.
[9]	National Comprehensive Cancer Network. Clinical practice guidelines in oncology: neuroendocrine and adrenal tumors (version 2. 2021)[EB/OL]. [2022-07-25]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448.
[10]	UEMURA J, OKANO K, OSHIMA M, et al. Immunohistochemically detected expression of ATRX, TSC2, and PTEN predicts clinical outcomes in patients with grade 1 and 2 pancreatic neuroendocrine tumors[J]. Ann Surg, 2021, 274(6): e949-e956. doi: 10.1097/SLA.0000000000003624
[11]	SCARPA A, CHANG D K, NONES K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours[J]. Nature, 2017, 543(7643): 65-71. doi: 10.1038/nature21063
[12]	JIAO Y C, SHI C J, EDIL B H, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors[J]. Science, 2011, 331(6021): 1199-1203. doi: 10.1126/science.1200609 pmid: 21252315
[13]	DI DOMENICO A, PIPINIKAS C P, MAIRE R S, et al. Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression[J]. Commun Biol, 2020, 3(1): 740. doi: 10.1038/s42003-020-01479-y pmid: 33288854
[14]	YOUNG K, LAWLOR R T, RAGULAN C, et al. Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours[J]. Gut, 2021, 70(10): 1904-1913. doi: 10.1136/gutjnl-2020-321016 pmid: 32883872
[15]	VERDE F, GALATOLA R, ROMEO V, et al. Pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1: diagnostic value of different MRI sequences[J]. Neuroendocrinology, 2021, 111(7): 696-704. doi: 10.1159/000509647
[16]	YOO J, KIM S H, JEON S K, et al. Added value of[⁶⁸Ga]Ga-DOTA-TOC PET/CT for characterizing pancreatic neuroendocrine neoplasms: a comparison with contrast-enhanced CT and/or MRI in a large study cohort[J]. Eur Radiol, 2021, 31(10): 7734-7745. doi: 10.1007/s00330-021-07859-0
[17]	PAIELLA S, LANDONI L, TEBALDI S, et al. Dual-tracer(⁶⁸Ga-DOTATOC and ¹⁸F-FDG-)-PET/CT scan and G1-G2 nonfunctioning pancreatic neuroendocrine tumors: a single-center retrospective evaluation of 124 nonmetastatic resected cases[J]. Neuroendocrinology, 2022, 112(2): 143-152. doi: 10.1159/000514809
[18]	VEENSTRA E B, DE GROOT D J A, BROUWERS A H, et al. Comparison of ¹⁸F-DOPA versus ⁶⁸Ga-DOTATOC as preferred PET imaging tracer in well-differentiated neuroendocrine neoplasms[J]. Clin Nucl Med, 2021, 46(3): 195-200. doi: 10.1097/RLU.0000000000003447
[19]	HSU D, LE S, CHANG A, et al. Should all pancreatic neuroendocrine tumors (PNET) over 1 cm be resected?[J]. J Clin Oncol, 2021, 39(15_suppl): 4108. doi: 10.1200/JCO.2021.39.15_suppl.4108
[20]	ALTIMARI M, ABAD J, CHAWLA A. The role of oncologic resection and enucleation for small pancreatic neuroendocrine tumors[J]. HPB (Oxford), 2021, 23(10): 1533-1540. doi: 10.1016/j.hpb.2021.03.005
[21]	SAHARA K, TSILIMIGRAS D I, MORO A, et al. Long-term outcomes after spleen-preserving distal pancreatectomy for pancreatic neuroendocrine tumors: results from the US neuroendocrine study group[J]. Neuroendocrinology, 2021, 111(1/2): 129-138. doi: 10.1159/000506399
[22]	ASANO D, KUDO A, AKAHOSHI K, et al. Curative surgery and Ki-67 value rather than tumor differentiation predict the survival of patients with high-grade neuroendocrine neoplasms[J]. Ann Surg, 2020, 276(2): e108-e113. doi: 10.1097/SLA.0000000000004495
[23]	张中国抗癌协会胰腺癌专业委员会. 中国胰腺癌综合诊治指南(2020版)[J]. 中华外科杂志, 2021, 59(2): 81-100.
	Pancreatic Cancer Committee of Chinese Anti-Cancer Association. Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer (2020 version)[J]. Chin J Surg, 2021, 59(2): 81-100.
[24]	TITAN A L, NORTON J A, FISHER A T, et al. Evaluation of outcomes following surgery for locally advanced pancreatic neuroendocrine tumors[J]. JAMA Netw Open, 2020, 3(11): e2024318.
[25]	PARGHANE R V, BHANDARE M, CHAUDHARI V, et al. Surgical feasibility, determinants, and overall efficacy of neoadjuvant ¹⁷⁷Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors[J]. J Nucl Med, 2021, 62(11): 1558-1563. doi: 10.2967/jnumed.120.258772
[26]	GAO H L, LIU L, WANG W Q, et al. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor[J]. Cancer Lett, 2018, 412: 188-193. doi: S0304-3835(17)30673-0 pmid: 29107104
[27]	WANG W Q, ZHANG W H, GAO H L, et al. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors[J]. J Gastroenterol, 2021, 56(4): 395-405. doi: 10.1007/s00535-021-01777-0
[28]	HEIDSMA C M, VAN ROESSEL S, VAN DIEREN S, et al. International validation of a nomogram to predict recurrence after resection of grade 1 and 2 nonfunctioning pancreatic neuroendocrine tumors[J]. Neuroendocrinology, 2022, 112(6): 571-579. doi: 10.1159/000518757
[29]	PULVIRENTI A, JAVED A A, LANDONI L, et al. Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors[J]. Ann Surg, 2021, 274(6): 1051-1057. doi: 10.1097/SLA.0000000000003579
[30]	KULKARNI R, KABIR I, HODSON J, et al. Impact of the extent of resection of neuroendocrine tumor liver metastases on survival: a systematic review and meta-analysis[J]. Ann Hepatobiliary Pancreat Surg, 2022, 26(1): 31-39. doi: 10.14701/ahbps.21-101
[31]	TSILIMIGRAS D I, HYER J M, PAREDES A Z, et al. Resection of primary gastrointestinal neuroendocrine tumor among patients with non-resected metastases is associated with improved survival: a SEER-medicare analysis[J]. J Gastrointest Surg, 2021, 25(9): 2368-2376. doi: 10.1007/s11605-020-04898-8 pmid: 33403563
[32]	KAEMMERER D, TWRZNIK M, KULKARNI H R, et al. Prior resection of the primary tumor prolongs survival after peptide receptor radionuclide therapy of advanced neuroendocrine neoplasms[J]. Ann Surg, 2021, 274(1): e45-e53. doi: 10.1097/SLA.0000000000003237 pmid: 33030849
[33]	MEROLA E, FALCONI M, RINKE A, et al. Radical intended surgery for highly selected stage Ⅳ neuroendocrine neoplasms G3[J]. Am J Surg, 2020, 220(2): 284-289. doi: 10.1016/j.amjsurg.2020.03.009
[34]	JANSON E T, KNIGGE U, DAM G, et al. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms[J]. Acta Oncol, 2021, 60(7): 931-941. doi: 10.1080/0284186X.2021.1921262
[35]	AL-TOUBAH T, MORSE B, PELLE E, et al. Efficacy of FOLFOX in patients with aggressive pancreatic neuroendocrine tumors after prior capecitabine/temozolomide[J]. Oncologist, 2021, 26(2): 115-119. doi: 10.1002/onco.13611
[36]	LACOMBE C, PERRIER M, HENTIC O, et al. FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors[J]. Ann Oncol, 2021, 32: S621.
[37]	DE RYCKE O, WALTER T, PERRIER M, et al. Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors[J]. Endocr Relat Cancer, 2021, 28(7): 457-466. doi: 10.1530/ERC-21-0034
[38]	MCGARRAH P W, HOBDAY T J, STARR J S, et al. Efficacy of somatostatin analog (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs)[J]. J Clin Oncol, 2020, 38(4_suppl): 617.
[39]	LEPAGE C, PHELIP J M, LIÈVRE A, et al. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours (NETs): an international double-blind, placebo-controlled randomized phase Ⅱ trial[J]. Ann Oncol, 2020, 31: S774.
[40]	DEHEZ M, BRENDEL K, SARR C, et al. CLARINET FORTE: characterization of pharmacokinetics (PK), efficacy and safety in patients with progressive neuroendocrine tumors (NETs) treated with lanreotide autogel (LAN) 120 mg every 14 days (q14d)[C]. 18th Annual ENETS Conference, 2021.
[41]	PAVEL M, ĆWIKŁA J B, LOMBARD-BOHAS C, et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results[J]. Eur J Cancer, 2021, 157: 403-414. doi: 10.1016/j.ejca.2021.06.056 pmid: 34597974
[42]	XU J M, SHEN L, BAI C M, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(11): 1489-1499. doi: 10.1016/S1470-2045(20)30493-9 pmid: 32966810
[43]	CAPDEVILA J, FAZIO N, LOPEZ C, et al. Lenvatinib in patients with advanced grade 1/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase Ⅱ TALENT trial (GETNE1509)[J]. J Clin Oncol, 2021, 39(20): 2304-2312. doi: 10.1200/JCO.20.03368
[44]	CLEMENT D, NAVALKISSOOR S, SRIRAJASKANTHAN R, et al. Efficacy and safety of ¹⁷⁷Lu-DOTATATE in patients (pts) with advanced pancreatic neuroendocrine tumors (pNETs): data from the NETTER-R international, retrospective registry[J]. J Clin Oncol, 2021, 39(15_suppl): 4116. doi: 10.1200/JCO.2021.39.15_suppl.4116
[45]	COFFMAN K L, BODEI L S, LE T, et al. Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to ¹⁷⁷Lu-DOTATATE[J]. J Clin Oncol, 2021, 39(3_suppl): 368. doi: 10.1200/JCO.2021.39.3_suppl.368
[46]	RINKE A, AUERNHAMMER C J, BODEI L S, et al. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?[J]. Gut, 2021, 70(9): 1768-1781. doi: 10.1136/gutjnl-2020-321300 pmid: 33692095
[47]	GRANDE E, RODRIGUEZ-ANTONA C, LÓPEZ C, et al. Sunitinib and evofosfamide (TH-302) in systemic treatment-naïve patients with grade 1/2 metastatic pancreatic neuroendocrine tumors: the GETNE-1408 trial[J]. Oncologist, 2021, 26(11): 941-949. doi: 10.1002/onco.13885
[48]	CORTI F, AMOROSO V, CAMPANA D, et al. Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): the phase Ⅱ LOLA trial[J]. J Clin Oncol, 2021, 39(15_suppl): TPS4167.
[49]	STROSBERG J, MIZUNO N, DOI T, et al. Efficacy and safety of pembrolizumab in previously treated advanced neuroendocrine tumors: results from the phase Ⅱ KEYNOTE-158 study[J]. Clin Cancer Res, 2020, 26(9): 2124-2130. doi: 10.1158/1078-0432.CCR-19-3014
[50]	HERNANDO J, MANZANO J L, TEULE A, et al. Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: results from the phase Ⅱ DUNE trial (GETNE 1601)[J]. Ann Oncol, 2021, 32: S909-S910. doi: 10.1016/j.annonc.2021.08.181
[51]	MANDRIANI B, PELLE E, MANNAVOLA F, et al. Development of CAR T-cells for future treatment of NETs[J]. Ann Oncol, 2021, 32: S911.
[52]	BUTT B P, STOKMO H L, LADEKARL M, et al. Folfirinox in the treatment of advanced gastroenteropancreatic neuroendocrine carsinomas[J]. Ann Oncol, 2021, 32: S915.
[53]	RIESCO-MARTINEZ M C, CAPDEVILA J, ALONSO V, et al. Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: preliminary results from the phase Ⅱ NICE-NEC trial (GETNE T1913)[J]. Ann Oncol, 2021, 32: S908-S909. doi: 10.1016/j.annonc.2021.08.180
[54]	SHEN L, YU X J, LU M, et al. Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: results from a multicenter, open-label, single-arm, phase Ⅱ trial[J]. J Clin Oncol, 2021, 39(15_suppl): e16199.